These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 7848024

  • 1. Blood pressure effects of the angiotensin II receptor blocker, losartan.
    Weber MA, Byyny RL, Pratt JH, Faison EP, Snavely DB, Goldberg AI, Nelson EB.
    Arch Intern Med; 1995 Feb 27; 155(4):405-11. PubMed ID: 7848024
    [Abstract] [Full Text] [Related]

  • 2. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS.
    Arch Intern Med; 1996 Feb 12; 156(3):278-85. PubMed ID: 8572837
    [Abstract] [Full Text] [Related]

  • 3. Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group.
    Byyny RL.
    Blood Press Suppl; 1996 Feb 12; 2():71-7. PubMed ID: 8913544
    [Abstract] [Full Text] [Related]

  • 4. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM, Goldberg AI.
    Blood Press Suppl; 1996 Feb 12; 2():82-6. PubMed ID: 8913546
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of losartan.
    Goldberg A, Sweet C.
    Can J Cardiol; 1995 Aug 12; 11 Suppl F():27F-32F. PubMed ID: 7664215
    [Abstract] [Full Text] [Related]

  • 6. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Varì N, Ferrara R, Bertocchi F.
    Clin Ther; 2004 Sep 12; 26(9):1436-45. PubMed ID: 15531006
    [Abstract] [Full Text] [Related]

  • 7. Controlling blood pressure throughout the day: issues in testing a new anti-hypertensive agent.
    Weber MA, Neutel JM, Smith DH.
    J Hum Hypertens; 1995 Nov 12; 9 Suppl 5():S29-35. PubMed ID: 8583478
    [Abstract] [Full Text] [Related]

  • 8. Losartan potassium as initial therapy in patients with severe hypertension.
    Dunlay MC, Fitzpatrick V, Chrysant S, Francischetti EA, Goldberg AI, Sweet CS.
    J Hum Hypertens; 1995 Nov 12; 9(11):861-7. PubMed ID: 8583463
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE, Kim YJ, Lee HY, Yang HM, Park CG, Kim JJ, Kim SK, Rhee MY, Oh BH, Investigators.
    Clin Ther; 2012 Mar 12; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H, Yang HM, Lee HY, Kim JJ, Choi DJ, Seung KB, Jeon ES, Ha JW, Rim SJ, Park JB, Shin JH, Oh BH.
    Clin Ther; 2012 Jun 12; 34(6):1273-89. PubMed ID: 22608107
    [Abstract] [Full Text] [Related]

  • 11. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Am J Hypertens; 1997 Jul 12; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [Abstract] [Full Text] [Related]

  • 12. Alterations in vascular structure and function after short-term losartan treatment in spontaneously hypertensive rats.
    Soltis EE.
    J Pharmacol Exp Ther; 1993 Aug 12; 266(2):642-6. PubMed ID: 8355197
    [Abstract] [Full Text] [Related]

  • 13. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr 12; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24-h ambulatory blood pressure monitoring, in essential hypertensive patients.
    de la Sierra A, Gil-Extremera B, Calvo C, Campo C, García-Puig J, Márquez E, Oliván J, Roca Cusachs A, Sanz de Castro S, Pontes C, Delgadillo J.
    J Hum Hypertens; 2004 Mar 12; 18(3):215-22. PubMed ID: 14973517
    [Abstract] [Full Text] [Related]

  • 15. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
    Gleim GW, Rubino J, Zhang H, Shahinfar S, Soffer BA, Lyle PA, Littlejohn TW, Feig PU.
    Clin Ther; 2006 Oct 12; 28(10):1639-48. PubMed ID: 17157119
    [Abstract] [Full Text] [Related]

  • 16. [Antihypertensive effect of valsartan 80 mg and hydrochlorothiazide 12.5 mg evaluated by ambulatory blood pressure monitoring].
    Vaïsse B, Ghobrial H, Vaur L, Poncelet P, Asmar R, Herpin D, Mallion JM.
    Arch Mal Coeur Vaiss; 2001 Aug 12; 94(8):907-12. PubMed ID: 11575229
    [Abstract] [Full Text] [Related]

  • 17. Effects of chronic treatment with losartan on blood pressure, endothelin-like immunoreactivity and nitric oxide in normotensive rats.
    Sacerdote A, Cosenzi A, Bocin E, Molino R, Seculin P, Plazzotta N, Luxich E, Bellini G.
    J Hypertens; 1995 Dec 12; 13(12 Pt 2):1670-3. PubMed ID: 8903630
    [Abstract] [Full Text] [Related]

  • 18. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I.
    Clin Ther; 2007 Feb 12; 29(2):279-89. PubMed ID: 17472820
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin II antagonists: a new class of antihypertensive agent.
    Waeber B, Brunner HR.
    Br J Clin Pract; 1996 Feb 12; 50(5):265-8. PubMed ID: 8794603
    [Abstract] [Full Text] [Related]

  • 20. Acute myocardial and vascular responses to specific angiotensin II antagonism in the spontaneously hypertensive rat.
    Cody RJ, Binkley PF, Haas GJ, Brown DM.
    Am J Hypertens; 1995 May 12; 8(5 Pt 1):500-8. PubMed ID: 7662227
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.